Latest From Hannah Daniel
Due to uncertainty in COVID-19 landscape in China, USANA adjusted its 2022 fiscal year guidance. Direct seller Mannatech decreased its number of fulfilled orders by 6% in the first quarter.
Tru Niagen sales made up more than 85% of first-quarter total, and TV ads launched in March drove a “dramatic increase” in customers, says CEO Robert Fried.
J&J's current consumer health division head, Thibaut Mongon, will be at the helm of its planned spinout of the business while Paul Ruh will move to the company was CFO.
Bausch Health closed Bausch + Lomb IPO offering 10% of shares instead of 20% planned. Bausch + Lomb’s $889m Q1 revenue up 1% while other Bausch Health divisions slumped.
In this episode, HBW Insight speaks to Michael Hufford, co-founder and CEO of Harm Reduction Therapeutics about the inaccessibility in the US of naloxone, a life-saving opioid overdose antidote. Hufford unpacks the history of naloxone access and explains why standing orders aren’t as helpful as they seem. We also explore the incentives for companies currently producing prescription naloxone to make the switch to OTC status, and why many of them have chosen not to. While the financial incentive may not be there, the public health need is dire, and Hufford explains the importance of harm reduction groups and non-profit pharmaceutical companies for getting naloxone into the hands of those who need it the most.
After a company-record FY2022, Prestige CEO Ron Lombardi says future inflationary pressures and supply chain issues should be “manageable.”